logo

Emergent Biosolutions Inc (EBS)



Trade EBS now with
  Date
  Headline
4/6/2020 6:34:51 AM Emergent BioSolutions Appoints Nina DeLorenzo As SVP Of Global Public Affairs
3/18/2020 6:40:31 AM Emergent Enters Agreement With Vaxart For Oral Vaccine Candidate For COVID-19
3/18/2020 6:33:32 AM Emergent To Deploy Molecule-to-market CDMO Services To Develop Vaxart’s Experimental Oral Vaccine For COVID-19
1/31/2020 10:09:06 AM Emergent BioSolutions Receives Positive CHMP Opinion For Vaxchora
1/13/2020 6:46:00 AM Emergent BioSolutions Now Sees FY Total Revenues Of $1.1 -$1.105 Bln
11/22/2019 8:24:17 AM Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study Of Chikungunya VLP Vaccine Candidate
10/10/2019 6:56:43 AM Emergent BioSolutions Receives EMA Prime Designation For Chikungunya Virus VLP Vaccine Candidate
9/27/2019 6:42:11 AM Emergent BioSolutions Receives NIH Research Grant To Further Develop AP007 For Addiction In Opioid Use Disorder
6/3/2019 6:43:45 AM Emergent BioSolutions Awarded 10-Yr HHS Contract Valued At About $535 Mln To Deliver VIGIV
6/3/2019 6:39:20 AM Emergent BioSolutions Secures 10-Yr HHS Contract Valued At $535 Mln
4/16/2019 6:34:45 AM Emergent BioSolutions Announces Interim Results From Phase 2 Study Of CHIKV-VLP, Chikungunya Virus Vaccine Candidate
3/19/2019 6:37:45 AM Emergent BioSolutions Begins Phase 3 Clinical Study To Evaluate AV7909
2/12/2019 6:37:16 AM Emergent BioSolutions Appoints Seamus Mulligan To Board
1/24/2019 7:07:12 AM Emergent BioSolutions Appoints Robert Kramer To Board